Refractory High Risk Myelodysplastic Syndrome
6 clinical trials · Condition
◉ Watch Refractory High Risk Myelodysplastic Syndrome
| Record | Firm | Date |
|---|---|---|
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT04047641) | M.D. Anderson Cancer Center | 2019-10-22 |
| CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT03896269) | M.D. Anderson Cancer Center | 2019-05-14 |
| Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome (NCT03383575) | M.D. Anderson Cancer Center | 2018-01-17 |
| Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome (NCT03359460) | University of California, Davis | 2017-12-01 |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS (NCT02921061) | Fred Hutchinson Cancer Center | 2016-11-17 |
Track Refractory High Risk Myelodysplastic Syndrome automatically
Every clearance here is in the API, with alerts when new ones post.